Purpose: Differences in acute adverse reactions to different gadolinium (Gd)-based contrast agents have not been thoroughly evaluated. We investigated the relationships among the incidence and severity of acute adverse reactions, backgrounds of patients, and 4 types of different Gd-based contrast agents (gadopentetate dimeglumine, gadoteridol, gadoterate meglumine, and gadoxetate disodium).
Introduction
Gadolinium (Gd)-based agents are the most widely used magnetic resonance (MR) imaging contrast materials. In Japan, 5 Gd-based contrast agents are available for clinical MR imaging studies. The conventional extracellular contrast agents are gadopentetate dimeglumine (Gd-DTPA), gadoteridol (Gd-DO3A), gadodiamide, and gadoterate meglumine (Gd-DOTA). A hepatocyte-specific Gd-based contrast agent, gadoxetate disodium (Gd-EOB-DTPA), has been introduced in clinical practice. These agents feature different molecular structures, charges, osmolarities, and viscosities.
Adverse effects elicited by Gd-based contrast agents have been reported, and the reported incidence of acute adverse reactions varies from 0.04 to 2.4%. [1] [2] [3] The incidence of acute adverse reactions is generally lower with Gd-based MR imaging contrast agents than with iodinated computed tomographic (CT) contrast agents (0.2 to 0.7%). [3] [4] [5] [6] In a retrospective study between 2002 and 2006, Hunt and associates 3 reported the incidence of adverse reactions to be 0.04% (64/158,439) for Gd-based MR imaging contrast agents and 0.15% (458/298,491) for iodinated-CT contrast agents. Mild acute adverse reactions are most common and include nausea with or without vomiting, headache, warmth at injection site, dizziness, and itching. Reactions resembling an "allergic" response, such as rash, hives, or urticaria, are unusual (0.004 to 0.7%), and life-threatening anaphylactoid reactions are extremely rare (0.001 to 0.01%). 2 Although recognition of the adverse effects of Gd-based contrast agents is important, the relationship between the incidence of acute adverse reactions and patient background and the type of Gdbased contrast agent used has not been thoroughly investigated. In our clinical practice, we use 4 types of contrast agents-Gd-DTPA, Gd-DO3A, Gd-DOTA, and Gd-EOB-DTPA. In August 2006, we adopted a policy of recording the incidence and severity of acute adverse reactions elicited by these agents. Here, we present the results of our retrospective survey.
Materials and Methods
Our institutional review board approved this retrospective study, and informed consent was waived.
Patients
Our cumulative radiology database included 10,595 consecutive patients (4,343 female, 6,252 male; mean age 63.8 « 14.0 years, range 9 to 97 years) who underwent contrast-enhanced MR imaging studies between August 2006 and March 2011. Of these, 1,290 (12.2%) had been administered Gdbased contrast media, including Gd-DTPA (Magnevist; Bayer Healthcare; 3,039 patients), Gd-DO3A (Prohance; Bracco-Eisai; 3,696 patients), Gd-DOTA (Magnescope; Terumo; 2,880 patients), or Gd-EOB-DTPA (Primovist; Bayer Healthcare; 980 patients). Table 1 delineates the characteristics of the agents.
The 3 contrast agents, Gd-DTPA, Gd-DO3A, and Gd-DOTA, were used for general clinical indications, i.e., evaluation of inflammatory diseases, orthopedic diseases, cardiovascular diseases, and oncological diseases including metastatic diseases. All patients who received Gd-EOB-DTPA underwent MR imaging to evaluate hepatocellular carcinoma, liver tumors, or liver metastases.
MR imaging and clinical data
Three 1.5-tesla MR imaging scanners were used (Excelart, Vantage, and Visart Ex; Toshiba Medical Systems, Nasu, Japan). Agents were delivered intravenously according to a dose calculated on the basis of body weight (0.1 mmol/kg for body imaging; 0.1 to 0.2 mmol/kg for brain imaging; and 0.05 mmol/ kg for hepatic imaging with Gd-EOB-DTPA). All doses were administered either manually (0.5 mL/s) or using a power injector (1.5 or 3.0 mL/s). Exclusion criteria for contrast-enhanced MR imaging included a known severe anaphylactoid reaction to Gdbased contrast agents, impaired renal function (estimated glomerular filtration rate 30 mL/min/1.73 m 2 or less), and pregnancy.
Acute adverse reactions were defined as reactions that developed within 60 min after contrast administration. The attending MR imaging radiologists assessed patients manifesting adverse reactions, and the MR imaging technologist and attending radiologists immediately recorded all acute adverse reactions in our radiology database. Complications elicited by acute adverse reactions were characterized as mild, moderate, and severe according to the criteria of the American College of Radiology (Table 2) . 2 The dose and injection rate of contrast agent were also recorded. The incidence of adverse reactions were compared on the basis of patient clinical characteristics, type of agent used, contrast dose, and contrast injection rate.
Statistical analysis
All numerical values are expressed as the mean « standard deviation (SD). We used chi-square test for 2 © 2, 3 © 2, and 4 © 2 tables to compare gender, injection rate, contrast agent dose, and types of 
] patterns for contrast types; therefore, P-values corrected by Bonferroni method were also presented for contrast injection rates and contrast types. For categorical comparison of the 4 different contrast agents using logistic regression analysis, 3 ORs for Gd-DO3A, Gd-DOTA, and Gd-EOB-DTPA were calculated in comparison with Gd-DTPA. We used JMP 9 software (SAS institute, Cary, NC, USA) for statistical analysis.
Results
Forty-eight (0.45%) of the 10,595 patients experienced acute adverse reactions. Table 3 shows the severity and symptoms of those reactions. No patient manifested multiple symptoms, and no severe adverse reaction was recorded. Forty-five of the 48 adverse reactions (93.75%) were mild, and three (6.25%) were moderate. Moderate reactions were observed in 2 patients who received Gd-DTPA and one patient who received Gd-DO3A. All patients improved during observation; none required inpatient care, and all were discharged. Of the 48 patients, six (12.50%) had a history of asthma and eight (16.67%) had a history of mild reaction to Gdbased contrast agents. Table 4 shows the relationship between adverse reactions and factors such as patient characteristics (sex and age), contrast dose, injection rate, and type of contrast agent. The incidence of adverse reactions did not differ significantly between male and female patients. Figure 1 shows the incidence of adverse reactions based on patient age.
The mean contrast dose was 13 mL (range, 5 to 25 mL). The injection rate, contrast dose, and type of contrast agent were not related to the incidence of adverse reactions (Table 4) . Adverse reactions were observed in 0.43% (13/3,039) of patients receiving Gd-DTPA, 0.54% (20/3696) receiving Gd-DO3A, 0.24% (7/2880) receiving Gd-DOTA, and 0.82% (8/ 980) receiving Gd-EOB-DTPA (Table 4) . Gd-EOB-DTPA showed the highest incidence of adverse reactions.
By univariate logistic analysis, P-values were 0.005 for patient age, 0.433 for patient sex, 0.352 (1.000 with the Bonferroni correction) for contrast injection rate, 0.988 for contrast dose, and 0.096 (0.576 with the Bonferroni correction) for type of contrast agent. P-values for patient age and type of contrast agent were 0.25 or less. Multivariate analysis demonstrated a significantly higher incidence of adverse reactions in younger patients (P = 0.002), although the odds ratio for patient age was 0.970 (Table 5 ). The OR was significantly higher for Gd-EOB (2.695) than Gd-DTPA (P = 0.043; Table 5 ).
Discussion
The overall safety of Gd-based contrast agents is considered to be excellent. 7 Our survey covering 5 years showed that only 48 of our 10,595 patients (0.45%) manifested immediate adverse reactions attributable to the contrast agent used, and all pa- tients recovered during observation. The incidence of overall reactions in our study was similar to that reported by others (0.17 to 0.67%), 8, 9 and similar to the findings of those studies, 8, 9 the most frequently adverse reaction we observed was nausea and/or vomiting (32 patients). Most adverse reactions in our patients were mild (93.75%); 6.25% suffered moderate reaction, and no patient manifested severe reaction. Our results showed relatively lower frequencies of moderate-to-severe reactions compared with those of previous studies. Jung and colleagues 10 reported 7.1% of 112 reactions were moderate and 9.8% were severe. Hunt and associates 3 reported the grading of up to 17.2% reactions as moderate and up to 6.3% as severe with respect to general radiology.
In contrast, Bruder's group 9 noted only mild reactions in a study of 17,767 patients with cardiovascular diseases who underwent MR imaging. Their result was similar to that in our study, even though the characteristics of our study populations differed. Anaphylactoid reactions involving respiratory, cardiovascular, cutaneous, gastrointestinal, and/or genitourinary manifestations have been reported, with apparent true incidence between 1/100,000 and 1/ 500,000. 11 Most patients with such reactions have a prior history of respiratory difficulties or respiratory allergic disease. 2 Although our study confirmed the safety of Gd-based contrast agents, a notable finding was that younger age tended to be a risk factor for acute adverse reactions, even though the OR was near one.
We found that the incidence of adverse reactions ranged from 0.24 to 0.82% for different contrast agents and was highest for Gd-EOB-DTPA, a paramagnetic hepatobiliary agent. Similarly to other Gdbased agents, Gd-EOB-DTPA behaves like a conventional extracellular contrast medium during the Gd-DTPA, gadopentetate dimeglumine; Gd-DO3A, gadoteridol; Gd-DOTA, gadoterate meglumine; Gd-EOB-DTPA, gadoxetate disodium Fig. 1 . Incidence of adverse reactions in different age ranges initial minutes after injection and is subsequently excreted by the kidneys and biliary system. 12 We posit that the higher incidence of reactions observed with Gd-EOB-DTPA was attributable to its greater degree of protein binding than that of other Gdbased agents. 13 In addition, Gd-EOB-DTPA could be used to evaluate hepatocellular carcinoma and metastasis or other liver tumors because the backgrounds of these patients were different from those of patients who received the other 3 Gd-contrast agents (Gd-DTPA, Gd-DO3A, and Gd-DOTA), which were used for general clinical purposes related not only to oncological diseases but also to inflammatory, orthopedic, and cardiovascular diseases. In a review of clinical Phase II and III studies that summarized safety data on Gd-EOB-DTPA, 13 120 of 1,404 patients (8.5%) experienced one or more adverse effects. The drug information sheets of Bayer Healthcare (available at http://www.info.pmda.go.jp/go/ pack/7290415G1020_1_07/) report that the rate of adverse effects of Gd-EOB-DTPA was 76/1755 (4.3%) for regulatory approval in Japan. Ichikawa and colleagues reported an incidence of adverse reactions to Gd-EOB-DTPA of 9.6%, 14 and we documented an even lower incidence (8/980, 0.82%). One reason for the discrepancy may be that we adopted a relatively slow injection of contrast agent (5,340 patients with 0.5 mL/s injection rate), and no patients experienced pain or swelling around the injection site. Other reasons may involve differences in patient populations and determination of adverse reactions. Ichikawa's team included various patient backgrounds and disease severities that could have influenced this discrepancy. Determination of the frequency of adverse reactions may often be difficult because similar signs and symptoms result from underlying disease, concomitant medical conditions, and medications. Further clinical studies are required to identify the incidence of adverse effects elicited by Gd-EOB-DTPA.
Our study has some limitations. First, we used a retrospective nonrandomized study design, and all patients were treated at a single institution. Multicenter prospective clinical trials are required to validate our data. Nonetheless, because our study population was relatively large and heterogeneous, we believe that our findings may be applicable in other settings. Second, we did not evaluate gadodiamide (Omniscan) because it was not used at our hospital. In addition, we did not assess gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) because these agents are not available in Japan. Third, we did not investigate the relationship between the incidence of adverse reactions and multiple exposures to contrast agents, though Jung and associates 10 reported them as a risk factor for adverse reactions. Finally, we evaluated only acute reactions and did not query our patients with respect to delayed reactions. Although the etiology of delayed reactions is unclear, concerns have been raised regarding the safety of residual chelate and/or the possible release of free Gd in patients with severe renal insufficiency. 7 We have not administered contrast agents to patients with severe renal insufficiency since 2006, and we have no evidence to suggest that any of our patients experienced severe delayed adverse effects.
In conclusion, we observed an only 0.45% incidence of acute adverse reactions after intravenous injection of Gd-based contrast agents. Younger individuals tended to be at higher risk for acute reactions, although the odds ratio (0.970) was near one. Our comparison of the incidence of acute adverse reactions revealed no significant differences among 4 Gd-based contrast agents but somewhat higher incidence with Gd-EOB-DTPA.
